Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Therapeutics

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2010.05.007PMID 20685493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

  2010cited by this paper
• Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization

  2010cited by this paper
• Tolerogenic Dendritic Cell-Regulatory T-cell Interaction and the Promotion of Transplant Tolerance

  2009cited by this paper
• CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

  2009cited by this paper
• Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

  2009cited by this paper
• Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

  2009cited by this paper
• Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

  2009cited by this paper
• Cost-Effective Use of Plerixafor for Hematopoietic Stem Cells Mobilization: Development and Validation of a Decision-Making Algorithm.

  2009cited by this paper
• AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties

  2009cited by this paper
• CXCR4 and mobilization of hematopoietic precursors.

  2009cited by this paper
• Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

  2009cited by this paper
• Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

  2009cited by this paper
• Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

  2009cited by this paper
• Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study

  2009cited by this paper
• A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.

  2008cited by this paper
• Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

  2008cited by this paper
• Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization

  2008cited by this paper
• Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.

  2008cited by this paper
• Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells

  2008cited by this paper
• Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.

  2008cited by this paper
• Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors

  2008cited by this paper
• AMD3100 and Granulocyte Colony Stimulating Factor (G-CSF) Mobilize Different CD34+ Cell Populations Based on Global Gene and Micro RNA Expression.

  2008cited by this paper
• AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

  2008cited by this paper
• AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.

  2007cited by this paper
• Pharmacokinetics of Plerixafor (AMD3100) in Volunteers with Renal Impairment.

  2007cited by this paper
• Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?

  2007cited by this paper
• Mobilization of Normal Mouse Progenitors and Acute Promyelocytic Leukemia (APL) Cells with Inhibitors of CXCR4 and VLA-4 in Splenectomized and Unsplenectomized Mice.

  2007cited by this paper
• In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis.

  2007cited by this paper
• Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies

  2007cited by this paper
• Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma

  2007cited by this paper
• Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.

  2007cited by this paper
• A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.

  2007cited by this paper
• Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.

  2007cited by this paper
• Improved Mobilization of Peripheral Blood CD34+ Cells and Dendritic Cells by AMD3100 plus Granulocyte–Colony-Stimulating Factor in Non-Hodgkin's Lymphoma Patients

  2007cited by this paper
• Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.

  2007cited by this paper
• Kinetics of Human and Murine Mobilization of Acute Myeloid Leukemia in Response to AMD3100.

  2007cited by this paper
• AMD3100 with G-CSF for Autologous Peripheral Blood Progenitor Cell (PBPC) Mobilization in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM): Mobilization, Engraftment, and Pharmacokinetics (PK).

  2006cited by this paper
• Steady State Mobilization of Autologous Blood Stem Cells Using G-CSF and AMD3100 in Patients with Multiple Myeloma (MM).

  2006cited by this paper
• The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.

  2006cited by this paper
• Cytokines and hematopoietic stem cell mobilization

  2006cited by this paper
• The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.

  2006cited by this paper
• HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

  2006cited by this paper
• In Vitro Chemotactic Index and Response to CXCR4 Antagonist AMD3100 Correlate with CD34+ Cell Yield from Leukapheresis Products: Implications for Poor Mobilizers.

  2006cited by this paper
• Kinetics of Autologous Stem Cell Mobilization Failure: Comparison of AMD3100/G-CSF, G-CSF, GM-/G-CSF, and Chemotherapy/G-CSF on Remobilization Success.

  2006cited by this paper
• Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization

  2006cited by this paper
• Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance.

  2006cited by this paper
• AMD3100 and G-CSF Synergize To Promote Repopulating Stem Cell Mobilization in Fanca −/− and Fancc −/− Mice.

  2006cited by this paper
• AMD3100 Inhibits Chemotaxis towards SDF-1 and CXCR4-Mediated Stroma-Contact in a Dose-Dependent Manner, Resulting in Increased Susceptibility to Imatinib.

  2006cited by this paper
• AMD3100 Signals Via the Nervous System, Inducing Release to the Circulation of Bone Marrow SDF-1, Which Is Crucial for Progenitor Cell Mobilization.

  2006cited by this paper
• Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation

  2006cited by this paper
• Phenotypic and Functional Analysis of T-Cells Mobilized in HLA-Matched Sibling Donors Following Treatment with the Chemokine Antagonist AMD3100.

  2006cited by this paper
• A Mobilizing Regimen of AMD3100 and G-CSF Increases Stem Cell Collection in Patients with Hodgkin’s Disease, and PK Is Similar to That of Non-Cancer Patients.

  2006cited by this paper
• Allograft Cell Content and GVHD Differ in Murine Recipients of AMD3100 Versus G-CSF Mobilized Peripheral Blood Stem Cells.

  2005cited by this paper
• The Role of the CXCR4 Inhibitor AMD3100 in Multiple Myeloma (MM).

  2005cited by this paper
• AMD3100 Mobilized Apheresis Products Are Rich in T-Cells That Do Not Undergo a Th-2 Type Cytokine Polarization: Implications for Allografting.

  2005cited by this paper
• G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism.

  2005cited by this paper
• CXCR4 Antagonists Mobilize Acute Lymphoblastic Leukemia Cells into the Peripheral Blood and Inhibit Engraftment in Mice.

  2005cited by this paper
• Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

  2005cited by this paper
• A Pharmacokinetic‐pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100

  2005cited by this paper
• How do stem cells find their way home?

  2005cited by this paper
• AMD3100 and G-CSF Mobilize Angiogenic Cells into the Blood of Healthy Donors.

  2005cited by this paper
• Comparison of CXCR-4 and Adhesion Molecule Expression in Healthy Bone Marrow with Expression in Bone Marrow and Peripheral Blood of Patients Receiving G-CSF Plus AMD3100.

  2005cited by this paper
• Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma.

  2005cited by this paper
• Human CD34+Cells Mobilized by AMD3100 Demonstrate Enhanced NOD/SCID Repopulating Function Compared to CD34+ Cells Mobilized by Granulocyte Colony Stimulating Factor.

  2005cited by this paper
• Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.

  2005cited by this paper
• The CXCR4 Antagonist AMD3100 Mobilizes a More Primitive Subset of CD34+ Cells Than G-CSF.

  2005cited by this paper
• AMD3100 Mobilizes Acute Promyelocytic Leukemia Cells from the Bone Marrow into the Peripheral Blood and Sensitizes Leukemia Cells to Chemotherapy.

  2005cited by this paper
• Kinetics of Hematopoietic Progenitor Cell Mobilization with Cyclophosphamide or Cyclophosphamide Plus AMD3100 Using a Mouse Model.

  2005cited by this paper
• The significance of cancer cell expression of the chemokine receptor CXCR4.

  2004cited by this paper
• Factors for PBPC collection efficiency and collection predictors.

  2004cited by this paper
• What Is the Optimum Number of CD34+ Peripheral Blood Stem Cells for an Autologous Transplant?

  2004cited by this paper
• Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

  2004cited by this paper
• A Comparison of the Ability of AMD3100 Versus G-CSF to Induce Angiogenesis and Mobilize Endothelial Progenitor Cells (EPCs).

  2004cited by this paper
• A Detailed Phenotypic Analysis Using Six Color Flow Cytometry of Lymphocyte Subsets Mobilized with AMD3100 Compared to G-CSF.

  2004cited by this paper
• The CXCR4 Antagonist, AMD3100, Inhibits AML Transmigratory Activity but Does Not Alter Blast Proliferation or Survival.

  2004cited by this paper
• Human CD34 + Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Equivalent Efficiency as CD34 + Cells Mobilized by G-CSF.

  2004cited by this paper
• Multilineage Analysis of Paired AMD-3100 and G-CSF Mobilized-Peripheral Blood Stem Cell Products from Healthy Donors Undergoing Clinical Mobilization: A Pilot Study.

  2004cited by this paper
• Cancer and the chemokine network

  2004cited by this paper
• G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4

  2002cited by this paper
• Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4

  2002cited by this paper
• Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation

  2002cited by this paper
• Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists.

  2001cited by this paper
• Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.

  2000cited by this paper
• Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers

  2000cited by this paper
• Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.

  2000cited by this paper
• Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment.

  2000cited by this paper
• Characterization and Outcome of “Hard to Mobilize” Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

  2000cited by this paper
• Predictive factors for long-term engraftment of autologous blood stem cells

  2000cited by this paper
• Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells

  2000cited by this paper
• Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose Chemotherapy

  1999cited by this paper
• Management strategies for the hard-to-mobilize patient

  1999cited by this paper
• Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.

  1999cited by this paper
• Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.

  1998cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial

  1997cited by this paper
• Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.

  1996cited by this paper
• Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.

  1995cited by this paper
• Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.

  1995cited by this paper
• Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.

  1995cited by this paper
• Autologous peripheral blood progenitor cell transplantation

  1995cited by this paper

• Overcoming Microenvironment-Driven Resistance to CAR-T Therapy in Multiple Myeloma

  2026cites this paper
• The cellular hierarchy of acute myeloid leukemia informs personalized treatment

  2024cites this paper
• Scale-Up Preparation of Best-In-Class Orally Bioavailable CXCR4 Antagonist EMU-116 in an Academic Setting

  2024cites this paper
• Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor

  2023cites this paper
• Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study.

  2023cites this paper
• The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma

  2021cites this paper
• Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old

  2021cites this paper
• A Multipurpose First‐in‐Human Study With the Novel CXCR7 Antagonist ACT‐1004‐1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker

  2021cites this paper
• Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation

  2021cites this paper
• Role of the Bone Marrow Niche in Supporting the Pathogenesis of Lymphoid Malignancies

  2021cites this paper
• Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer

  2021cites this paper
• GPCRs as an emerging host‐directed therapeutic target against mycobacterial infection: From notion to reality

  2020cites this paper
• Role of Chemokines in the Biology of Cholangiocarcinoma

  2020cites this paper
• The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma

  2019cites this paper
• Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization.

  2019cites this paper
• Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters.

  2019cites this paper
• Structural Basis for Allosteric Ligand Recognition in the Human CC Chemokine Receptor 7

  2019cites this paper
• Anatomical structure, and expression of CCL4 and CCL13-like during the development of maxillary barbel in Paramisgurnus dabryanus

  2019cites this paper
• Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy

  2018cites this paper
• Chemokine C-C motif ligand 33 is a key regulator of teleost fish barbel development

  2018cites this paper
• Chemokines in homeostasis and diseases

  2018cites this paper
• Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single‐center observational study

  2017cites this paper
• Cellular therapy for myocardial ischemia using a temperature-responsive biodegradable injectable polymer system with adipose-derived stem cells

  2017cites this paper
• Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers

  2017influential citation
• Development and testing of multi-modal, multi-scale imaging systems for rare-earth-doped contrast agents

  2016cites this paper
• Stem Cell Mobilization Protocols : Filgrastim vs . Mozobil

  2016cites this paper
• Tissue inhibitor of metalloproteinases (TIMP)‐1 creates a premetastatic niche in the liver through SDF‐1/CXCR4‐dependent neutrophil recruitment in mice

  2015cites this paper
• Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome

  2015cites this paper
• Role of the CXCR4/SDF-1 Chemokine Axis in Metastasis Formation in Osteosarcoma

  2015cites this paper
• Dual Targeting of the Chemokine Receptors CXCR4 and ACKR3 with Novel Engineered Chemokines*

  2015cites this paper
• The Intricate Role of CXCR 4 in Cancer

  2015cites this paper
• The intricate role of CXCR4 in cancer.

  2014cites this paper
• Cancer Therapy : Clinical The High-Af fi nity CXCR 4 Antagonist BKT 140 Is Safe and Induces a Robust Mobilization of Human CD 34 þ Cells in Patients with Multiple Myeloma

  2014cites this paper
• Role of 3D Structures in Understanding, Predicting, and Designing Molecular Interactions in the Chemokine Receptor Family

  2014cites this paper
• Relation fonctionnelle entre CXCR4 et CXCR7 dans le contrôle de la migration chimiotactique vers CXCL12

  2014cites this paper
• The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

  2013cites this paper
• Mechanisms of radiation-induced skin injury and implications for future clinical trials

  2013cites this paper
• Regulatory Systems in Bone Marrow for Hematopoietic Stem/Progenitor Cells Mobilization and Homing

  2013cites this paper
• The high-affinity CXCR 4 antagonist BKT 140 is safe and induces a robust mobilization of human CD 34 + cells in patients with multiple myeloma

  2013cites this paper
• CXC-Chemokine Receptor 4 Antagonist AMD3100 Promotes Cardiac Functional Recovery After Ischemia/Reperfusion Injury via Endothelial Nitric Oxide Synthase–Dependent Mechanism

  2012cites this paper
• Stem Cell Mobilization with Chemomobilization Plus Plerixafor in Hard-to-Mobilize Patients: The Experience at Kuopio University Hospital, Finland

  2012cites this paper
• Using rHuG-CSF in Multiple Myeloma: Consolidated Data, Evolutions, and New Concepts

  2012cites this paper
• Mobilization of Hematopoietic Stem Cells in Patients with Multiple Myeloma Utilizing Growth Factor Combined with Plerixafor

  2012cites this paper
• Movilización de células hematopoyéticas con plerixafor en linfoma no Hodgkin folicular

  2012cites this paper
• Preemptive use of plerixafor in difficult‐to‐mobilize patients: an emerging concept

  2012cites this paper
• Development of novel CXCR4-based therapeutics

  2012cites this paper
• Granulocyte colony stimulating factor expands hematopoietic stem cells within the central but not endosteal bone marrow region.

  2012cites this paper
• CXC-Chemokine Receptor 4 Antagonist AMD3100 Promotes Cardiac Functional Recovery After Ischemia/Reperfusion Injury via Endothelial Nitric Oxide Synthase–Dependent Mechanism

  2012cites this paper
• Current status of chemokine receptor inhibitors in development.

  2012cites this paper
• Progenitor Cells as a Bridging Therapy for Radiation Casualties

  2011cites this paper
• Design and synthesis of a library of chemokine antagonists.

  2011cites this paper
• Efficacy of pre‐emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience

  2011cites this paper
• Les différentes modalités de prélèvement des cellules souches hématopoïétiques

  2011cites this paper
• Homeostatic chemokine receptors and organ-specific metastasis

  2011cites this paper
• Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

  2011cites this paper
• [The methods used to collect hematopoietic stem cells].

  2011cites this paper
• Novel strategies for blood stem cell mobilization: special focus on plerixafor

  2011cites this paper
• Mobilized progenitor cells as a bridging therapy for radiation casualties: a brief review of tocopherol succinate-based approaches.

  2011cites this paper